Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of V72_28: Antibody Persistence and Booster Dose Safety for Meningococcal B Vaccine
2012-000657-30Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease, sponsored by Novartis. Primary endpoints: Antibody persistence 24–36 months after primary vaccination course and Safety and tolerability of a booster dose. Started Apr 2013; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-000657-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000657-30.